Jennifer L Saullo1, Arthur W Baker2, Laurie D Snyder3, John M Reynolds3, Lorenzo Zaffiri3, Emily M Eichenberger4, Alana Ferrari5, Julie M Steinbrink4, Eileen K Maziarz4, Melissa Bacchus4, Holly Berry6, Stylianos A Kakoullis7, Cameron R Wolfe4. 1. Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina. Electronic address: jennifer.horan@duke.edu. 2. Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina; Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina. 3. Division of Pulmonary, Allergy and Critical Care, Duke University School of Medicine, Durham, North Carolina. 4. Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina. 5. Department of Pharmacy, University of Virginia Medical Center, Charlottesville, Virginia. 6. Department of Pharmacy, Duke University Medical Center, Durham, North Carolina. 7. Division of Pulmonary and Intensive Care Medicine, European University of Cyprus School of Medicine, Engomi, Nicosia Cyprus.
Abstract
BACKGROUND: Cytomegalovirus (CMV) infection is common following thoracic organ transplantation and causes substantial morbidity and mortality. Letermovir is a novel antiviral agent used off-label in this population for CMV prevention. Our goal was to understand patterns of letermovir use and effectiveness when applied for CMV prophylaxis after thoracic transplantation. METHODS: We retrospectively evaluated letermovir use among thoracic transplant recipients at an academic transplant center who initiated letermovir from January 2018 to October2019 for CMV prophylaxis. We analyzed indication, timing, and duration of prophylaxis; tolerability; and occurrence of breakthrough CMV DNAemia and disease. RESULTS: Forty-two episodes of letermovir prophylaxis occurred in 41 patients, including 37 lung and 4 heart transplant recipients. Primary prophylaxis (26/42, 61.9%) was utilized mainly due to myelosuppression (25/26, 96.2%) and was initiated a median of 315 days post-transplant (interquartile range [IQR] 125-1139 days). Sixteen episodes of secondary prophylaxis (16/42, 38.1%) were initiated a median of 695 days post-transplant (IQR 537-1156 days) due to myelosuppression (10/16, 62.5%) or prior CMV resistance (6/16, 37.5%). Median duration of letermovir prophylaxis was 282 days (IQR 131-433 days). Adverse effects required letermovir cessation in 5/42 (11.9%) episodes. Only one episode (2.4%) was complicated by clinically significant breakthrough CMV infection. Transient low-level CMV DNAemia (<450 IU/ml) occurred in 15 episodes (35.7%) but did not require letermovir cessation. CONCLUSIONS: Letermovir was well tolerated and effective during extended prophylactic courses with only one case of breakthrough CMV infection in this cohort of thoracic transplant recipients. Further prospective trials of letermovir prophylaxis in this population are warranted.
BACKGROUND: Cytomegalovirus (CMV) infection is common following thoracic organ transplantation and causes substantial morbidity and mortality. Letermovir is a novel antiviral agent used off-label in this population for CMV prevention. Our goal was to understand patterns of letermovir use and effectiveness when applied for CMV prophylaxis after thoracic transplantation. METHODS: We retrospectively evaluated letermovir use among thoracic transplant recipients at an academic transplant center who initiated letermovir from January 2018 to October2019 for CMV prophylaxis. We analyzed indication, timing, and duration of prophylaxis; tolerability; and occurrence of breakthrough CMV DNAemia and disease. RESULTS: Forty-two episodes of letermovir prophylaxis occurred in 41 patients, including 37 lung and 4 heart transplant recipients. Primary prophylaxis (26/42, 61.9%) was utilized mainly due to myelosuppression (25/26, 96.2%) and was initiated a median of 315 days post-transplant (interquartile range [IQR] 125-1139 days). Sixteen episodes of secondary prophylaxis (16/42, 38.1%) were initiated a median of 695 days post-transplant (IQR 537-1156 days) due to myelosuppression (10/16, 62.5%) or prior CMV resistance (6/16, 37.5%). Median duration of letermovir prophylaxis was 282 days (IQR 131-433 days). Adverse effects required letermovir cessation in 5/42 (11.9%) episodes. Only one episode (2.4%) was complicated by clinically significant breakthrough CMV infection. Transient low-level CMV DNAemia (<450 IU/ml) occurred in 15 episodes (35.7%) but did not require letermovir cessation. CONCLUSIONS: Letermovir was well tolerated and effective during extended prophylactic courses with only one case of breakthrough CMV infection in this cohort of thoracic transplant recipients. Further prospective trials of letermovir prophylaxis in this population are warranted.
Authors: A P Wiita; N Roubinian; Y Khan; P V Chin-Hong; J P Singer; J A Golden; S Miller Journal: Transpl Infect Dis Date: 2012-03-05 Impact factor: 2.228
Authors: Scott M Palmer; Ajit P Limaye; Missy Banks; Dianne Gallup; Jeffrey Chapman; E Clinton Lawrence; Jordan Dunitz; Aaron Milstone; John Reynolds; Gordon L Yung; Kevin M Chan; Robert Aris; Edward Garrity; Vincent Valentine; Jonathan McCall; Shein-Chung Chow; Robert Duane Davis; Robin Avery Journal: Ann Intern Med Date: 2010-06-15 Impact factor: 25.391
Authors: Uta S Koepf; Hans U Klehr; Anna-M Eis-Huebinger; Souhaib Aldabbagh; Christian P Strassburg; Dominik Boes; Philipp Lutz Journal: Eur J Case Rep Intern Med Date: 2020-04-20
Authors: Nicholas Turner; Andrew Strand; Dilraj S Grewal; Gary Cox; Sana Arif; Arthur W Baker; Eileen K Maziarz; Jennifer H Saullo; Cameron R Wolfe Journal: Antimicrob Agents Chemother Date: 2019-02-26 Impact factor: 5.191
Authors: Per Ljungman; Michael Boeckh; Hans H Hirsch; Filip Josephson; Jens Lundgren; Garrett Nichols; Andreas Pikis; Raymund R Razonable; Veronica Miller; Paul D Griffiths Journal: Clin Infect Dis Date: 2016-09-28 Impact factor: 9.079
Authors: Cameron M Douglas; Richard Barnard; Daniel Holder; Randi Leavitt; Diane Levitan; Maureen Maguire; David Nickle; Valerie Teal; Hong Wan; Dirk C J G van Alewijk; Leen-Jan van Doorn; Sunwen Chou; Julie Strizki Journal: J Infect Dis Date: 2020-03-16 Impact factor: 5.226
Authors: Martin Stern; Hans Hirsch; Alexia Cusini; Christian van Delden; Oriol Manuel; Pascal Meylan; Katia Boggian; Nicolas J Mueller; Michael Dickenmann Journal: Transplantation Date: 2014-11-15 Impact factor: 4.939